Gina Kruse
Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking Cessation | 18 | 2025 | 431 | 6.830 |
Why?
| | Early Detection of Cancer | 9 | 2026 | 432 | 2.880 |
Why?
| | Text Messaging | 5 | 2023 | 179 | 2.300 |
Why?
| | Tobacco Use Cessation | 3 | 2025 | 28 | 1.830 |
Why?
| | Smoking | 9 | 2026 | 1576 | 1.790 |
Why?
| | Primary Health Care | 7 | 2023 | 1757 | 1.270 |
Why?
| | Massachusetts | 9 | 2026 | 176 | 1.210 |
Why?
| | Electronic Nicotine Delivery Systems | 6 | 2026 | 106 | 1.110 |
Why?
| | Tobacco Use | 3 | 2022 | 65 | 1.060 |
Why?
| | Smokers | 4 | 2020 | 146 | 1.020 |
Why?
| | Varenicline | 2 | 2025 | 28 | 0.980 |
Why?
| | Uterine Cervical Neoplasms | 3 | 2025 | 268 | 0.970 |
Why?
| | Tobacco Products | 3 | 2025 | 91 | 0.970 |
Why?
| | Colorectal Neoplasms | 4 | 2025 | 811 | 0.960 |
Why?
| | Behavior Therapy | 3 | 2025 | 282 | 0.940 |
Why?
| | Tobacco Use Disorder | 3 | 2022 | 237 | 0.920 |
Why?
| | Intention | 1 | 2026 | 180 | 0.840 |
Why?
| | Peer Group | 1 | 2026 | 248 | 0.830 |
Why?
| | Postal Service | 2 | 2020 | 30 | 0.810 |
Why?
| | Buprenorphine | 2 | 2025 | 181 | 0.810 |
Why?
| | Opioid-Related Disorders | 3 | 2026 | 568 | 0.790 |
Why?
| | HIV Infections | 8 | 2025 | 2981 | 0.780 |
Why?
| | Lung Neoplasms | 2 | 2026 | 2554 | 0.740 |
Why?
| | Laboratories | 1 | 2023 | 106 | 0.730 |
Why?
| | Community Health Services | 2 | 2015 | 232 | 0.730 |
Why?
| | Social Support | 1 | 2026 | 629 | 0.710 |
Why?
| | United States Indian Health Service | 2 | 2022 | 46 | 0.680 |
Why?
| | Patient Discharge | 3 | 2024 | 915 | 0.660 |
Why?
| | Mentoring | 1 | 2023 | 150 | 0.630 |
Why?
| | Humans | 62 | 2026 | 141284 | 0.620 |
Why?
| | Electronic Health Records | 4 | 2016 | 1129 | 0.610 |
Why?
| | Alaska Natives | 1 | 2022 | 154 | 0.610 |
Why?
| | Health Behavior | 3 | 2022 | 784 | 0.560 |
Why?
| | Papillomavirus Infections | 1 | 2023 | 364 | 0.560 |
Why?
| | Delivery of Health Care | 4 | 2023 | 948 | 0.550 |
Why?
| | Community Health Centers | 5 | 2025 | 63 | 0.540 |
Why?
| | Female | 39 | 2026 | 75814 | 0.540 |
Why?
| | Middle Aged | 25 | 2026 | 34658 | 0.540 |
Why?
| | Telemedicine | 3 | 2025 | 893 | 0.540 |
Why?
| | Pilot Projects | 6 | 2025 | 1820 | 0.530 |
Why?
| | Male | 34 | 2026 | 70140 | 0.520 |
Why?
| | Adult | 30 | 2026 | 39319 | 0.520 |
Why?
| | Rural Population | 3 | 2024 | 602 | 0.500 |
Why?
| | Meaningful Use | 1 | 2016 | 13 | 0.500 |
Why?
| | Indians, North American | 1 | 2022 | 655 | 0.480 |
Why?
| | Comorbidity | 2 | 2017 | 1671 | 0.450 |
Why?
| | Motivation | 2 | 2019 | 600 | 0.450 |
Why?
| | Cross-Sectional Studies | 11 | 2026 | 5653 | 0.440 |
Why?
| | Smoke-Free Policy | 1 | 2014 | 13 | 0.440 |
Why?
| | India | 3 | 2025 | 210 | 0.440 |
Why?
| | Smoking Prevention | 1 | 2015 | 170 | 0.430 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 54 | 0.420 |
Why?
| | Hospitalization | 3 | 2025 | 2264 | 0.420 |
Why?
| | Opiate Substitution Treatment | 3 | 2025 | 170 | 0.410 |
Why?
| | Tobacco Smoking | 2 | 2024 | 25 | 0.400 |
Why?
| | Reimbursement, Incentive | 1 | 2013 | 40 | 0.390 |
Why?
| | Program Development | 1 | 2015 | 364 | 0.390 |
Why?
| | Counseling | 4 | 2024 | 395 | 0.390 |
Why?
| | Vaping | 2 | 2025 | 63 | 0.380 |
Why?
| | United States | 12 | 2026 | 15298 | 0.370 |
Why?
| | Colonoscopy | 1 | 2014 | 250 | 0.360 |
Why?
| | Tobacco Smoke Pollution | 1 | 2014 | 238 | 0.360 |
Why?
| | Health Equity | 3 | 2024 | 107 | 0.360 |
Why?
| | Documentation | 1 | 2013 | 194 | 0.350 |
Why?
| | Telephone | 2 | 2023 | 181 | 0.340 |
Why?
| | Population Surveillance | 1 | 2014 | 481 | 0.340 |
Why?
| | Neoplasms | 2 | 2023 | 2731 | 0.330 |
Why?
| | Aged | 14 | 2026 | 24836 | 0.320 |
Why?
| | Anti-HIV Agents | 2 | 2014 | 853 | 0.300 |
Why?
| | Qualitative Research | 4 | 2026 | 1519 | 0.290 |
Why?
| | Referral and Consultation | 2 | 2012 | 802 | 0.280 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2025 | 1610 | 0.280 |
Why?
| | Students | 2 | 2022 | 644 | 0.250 |
Why?
| | Oklahoma | 1 | 2026 | 14 | 0.240 |
Why?
| | Boston | 3 | 2024 | 91 | 0.240 |
Why?
| | Flavoring Agents | 1 | 2025 | 13 | 0.230 |
Why?
| | Commerce | 1 | 2026 | 74 | 0.230 |
Why?
| | South Africa | 2 | 2024 | 200 | 0.230 |
Why?
| | Feasibility Studies | 2 | 2022 | 1037 | 0.220 |
Why?
| | Appointments and Schedules | 2 | 2002 | 102 | 0.220 |
Why?
| | Alcohol-Related Disorders | 1 | 2025 | 127 | 0.210 |
Why?
| | Pandemics | 3 | 2021 | 1655 | 0.210 |
Why?
| | Faculty | 2 | 2022 | 153 | 0.210 |
Why?
| | Occult Blood | 1 | 2024 | 38 | 0.210 |
Why?
| | Patient Compliance | 2 | 2012 | 607 | 0.200 |
Why?
| | Outpatients | 2 | 2024 | 425 | 0.200 |
Why?
| | Mental Disorders | 2 | 2002 | 1133 | 0.200 |
Why?
| | Social Determinants of Health | 2 | 2024 | 275 | 0.200 |
Why?
| | Health Policy | 1 | 2026 | 385 | 0.190 |
Why?
| | Narcotic Antagonists | 1 | 2025 | 193 | 0.190 |
Why?
| | Cost-Benefit Analysis | 1 | 2025 | 612 | 0.190 |
Why?
| | Vaginal Smears | 1 | 2023 | 56 | 0.190 |
Why?
| | Safety-net Providers | 1 | 2024 | 124 | 0.190 |
Why?
| | Cooperative Behavior | 1 | 2025 | 456 | 0.190 |
Why?
| | Papillomaviridae | 1 | 2023 | 121 | 0.180 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2002 | 83 | 0.180 |
Why?
| | Interrupted Time Series Analysis | 1 | 2022 | 72 | 0.180 |
Why?
| | Medically Underserved Area | 1 | 2022 | 99 | 0.180 |
Why?
| | Treatment Refusal | 1 | 2002 | 96 | 0.180 |
Why?
| | Student Run Clinic | 1 | 2021 | 2 | 0.180 |
Why?
| | Mass Screening | 3 | 2025 | 1309 | 0.180 |
Why?
| | Tuberculosis | 1 | 2024 | 281 | 0.180 |
Why?
| | Patient Participation | 1 | 2005 | 427 | 0.170 |
Why?
| | Pain Management | 1 | 2005 | 397 | 0.170 |
Why?
| | Medication Adherence | 1 | 2025 | 510 | 0.170 |
Why?
| | Education, Medical, Undergraduate | 1 | 2023 | 198 | 0.160 |
Why?
| | Developing Countries | 2 | 2015 | 308 | 0.160 |
Why?
| | Physician-Patient Relations | 1 | 2005 | 579 | 0.160 |
Why?
| | Prevalence | 4 | 2025 | 2795 | 0.160 |
Why?
| | Community Networks | 1 | 2020 | 57 | 0.160 |
Why?
| | Longitudinal Studies | 2 | 2020 | 2929 | 0.160 |
Why?
| | Interviews as Topic | 3 | 2019 | 839 | 0.150 |
Why?
| | Education, Medical | 1 | 2023 | 271 | 0.150 |
Why?
| | Ambulatory Care | 1 | 2024 | 592 | 0.150 |
Why?
| | Crisis Intervention | 1 | 2019 | 33 | 0.150 |
Why?
| | Young Adult | 7 | 2025 | 13727 | 0.150 |
Why?
| | Pain | 1 | 2005 | 779 | 0.150 |
Why?
| | Alcoholism | 1 | 2025 | 823 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2024 | 1117 | 0.140 |
Why?
| | Preventive Health Services | 1 | 2020 | 154 | 0.140 |
Why?
| | Nevirapine | 2 | 2008 | 18 | 0.140 |
Why?
| | Cohort Studies | 5 | 2025 | 5809 | 0.140 |
Why?
| | Students, Medical | 1 | 2023 | 370 | 0.140 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2026 | 1395 | 0.130 |
Why?
| | Organophosphonates | 2 | 2008 | 96 | 0.130 |
Why?
| | Decision Making | 1 | 2005 | 949 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2019 | 5948 | 0.130 |
Why?
| | Liver Transplantation | 1 | 2024 | 768 | 0.130 |
Why?
| | Deoxycytidine | 2 | 2008 | 202 | 0.130 |
Why?
| | Adolescent | 8 | 2025 | 22116 | 0.130 |
Why?
| | Communication | 1 | 2023 | 941 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2021 | 374 | 0.120 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2008 | 186 | 0.120 |
Why?
| | Texas | 4 | 2005 | 267 | 0.120 |
Why?
| | Hypertension | 1 | 2024 | 1250 | 0.120 |
Why?
| | Diabetes Mellitus | 1 | 2024 | 1078 | 0.120 |
Why?
| | Diffusion of Innovation | 1 | 2016 | 96 | 0.120 |
Why?
| | Caregivers | 1 | 2024 | 940 | 0.120 |
Why?
| | Adenine | 2 | 2008 | 335 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 1 | 2026 | 2765 | 0.110 |
Why?
| | Focus Groups | 2 | 2022 | 565 | 0.110 |
Why?
| | Allied Health Personnel | 1 | 2015 | 53 | 0.110 |
Why?
| | Automobiles | 1 | 2014 | 18 | 0.110 |
Why?
| | Health Surveys | 1 | 2017 | 511 | 0.110 |
Why?
| | Community Health Workers | 1 | 2015 | 78 | 0.110 |
Why?
| | Logistic Models | 3 | 2017 | 2098 | 0.110 |
Why?
| | Uganda | 1 | 2014 | 86 | 0.110 |
Why?
| | Colonic Polyps | 1 | 2014 | 82 | 0.100 |
Why?
| | Odds Ratio | 3 | 2008 | 1057 | 0.100 |
Why?
| | Program Evaluation | 2 | 2020 | 919 | 0.100 |
Why?
| | Residence Characteristics | 2 | 2014 | 367 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1105 | 0.100 |
Why?
| | Patient Admission | 1 | 2014 | 203 | 0.090 |
Why?
| | Managed Care Programs | 1 | 2013 | 140 | 0.090 |
Why?
| | Hospitals, Psychiatric | 2 | 2002 | 27 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2021 | 1124 | 0.090 |
Why?
| | Social Class | 1 | 2014 | 269 | 0.090 |
Why?
| | Health Services Accessibility | 4 | 2024 | 1030 | 0.090 |
Why?
| | HIV-1 | 2 | 2008 | 882 | 0.090 |
Why?
| | Prospective Studies | 3 | 2025 | 7805 | 0.090 |
Why?
| | Nurses | 1 | 2014 | 183 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 3 | 2022 | 874 | 0.090 |
Why?
| | Feedback | 1 | 2012 | 177 | 0.090 |
Why?
| | Health Plan Implementation | 1 | 2012 | 142 | 0.090 |
Why?
| | Quality Assurance, Health Care | 1 | 2013 | 319 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2024 | 5222 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 2210 | 0.080 |
Why?
| | Hospitals | 1 | 2014 | 688 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2529 | 0.070 |
Why?
| | Retrospective Studies | 4 | 2022 | 16447 | 0.070 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2007 | 86 | 0.070 |
Why?
| | Chronic Disease | 1 | 2013 | 1807 | 0.060 |
Why?
| | Patient Care Team | 1 | 2012 | 667 | 0.060 |
Why?
| | Drug Resistance, Viral | 1 | 2007 | 121 | 0.060 |
Why?
| | Licensure | 1 | 2026 | 14 | 0.060 |
Why?
| | Anti-Retroviral Agents | 1 | 2008 | 240 | 0.060 |
Why?
| | Renal Insufficiency | 1 | 2008 | 170 | 0.060 |
Why?
| | Behavioral Risk Factor Surveillance System | 1 | 2025 | 53 | 0.060 |
Why?
| | Risk Factors | 2 | 2014 | 10490 | 0.060 |
Why?
| | Insurance, Health | 2 | 2005 | 296 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2024 | 7948 | 0.060 |
Why?
| | Regression Analysis | 2 | 2005 | 1013 | 0.060 |
Why?
| | Insurance Coverage | 2 | 2022 | 239 | 0.050 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2008 | 408 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2022 | 1043 | 0.050 |
Why?
| | Quality Improvement | 1 | 2012 | 1241 | 0.050 |
Why?
| | Vaccination | 2 | 2022 | 1468 | 0.050 |
Why?
| | Housing | 1 | 2024 | 146 | 0.050 |
Why?
| | Social Networking | 1 | 2023 | 36 | 0.050 |
Why?
| | Mobile Health Units | 1 | 2022 | 20 | 0.050 |
Why?
| | Rural Health Services | 1 | 2004 | 140 | 0.050 |
Why?
| | Midwestern United States | 1 | 2002 | 44 | 0.050 |
Why?
| | Health Services for the Aged | 1 | 2003 | 72 | 0.050 |
Why?
| | Health Status | 2 | 2005 | 822 | 0.050 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2022 | 126 | 0.050 |
Why?
| | Hospitals, University | 1 | 2002 | 176 | 0.050 |
Why?
| | Bupropion | 1 | 2022 | 45 | 0.040 |
Why?
| | Stakeholder Participation | 1 | 2022 | 80 | 0.040 |
Why?
| | Schools, Medical | 1 | 2023 | 154 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2007 | 748 | 0.040 |
Why?
| | Quality of Life | 2 | 2022 | 3024 | 0.040 |
Why?
| | Continuity of Patient Care | 1 | 2004 | 282 | 0.040 |
Why?
| | England | 1 | 2021 | 108 | 0.040 |
Why?
| | Meals | 1 | 2022 | 132 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2022 | 170 | 0.040 |
Why?
| | HIV | 1 | 2022 | 248 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2025 | 938 | 0.040 |
Why?
| | Data Collection | 1 | 2024 | 655 | 0.040 |
Why?
| | Minority Groups | 1 | 2022 | 278 | 0.040 |
Why?
| | Poverty | 1 | 2024 | 527 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1265 | 0.040 |
Why?
| | Urban Population | 1 | 2003 | 482 | 0.040 |
Why?
| | Triage | 1 | 2021 | 250 | 0.040 |
Why?
| | Learning | 1 | 2023 | 434 | 0.040 |
Why?
| | Medicaid | 1 | 2003 | 450 | 0.040 |
Why?
| | Age Factors | 1 | 2026 | 3295 | 0.040 |
Why?
| | Zambia | 2 | 2008 | 52 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2012 | 11216 | 0.030 |
Why?
| | Medicare | 1 | 2003 | 802 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1546 | 0.030 |
Why?
| | Emtricitabine | 2 | 2008 | 204 | 0.030 |
Why?
| | Tenofovir | 2 | 2008 | 288 | 0.030 |
Why?
| | Curriculum | 1 | 2023 | 1035 | 0.030 |
Why?
| | Child | 2 | 2024 | 22390 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3577 | 0.020 |
Why?
| | Socioeconomic Factors | 2 | 2004 | 1311 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 526 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2008 | 278 | 0.020 |
Why?
| | Creatinine | 1 | 2008 | 491 | 0.020 |
Why?
| | Risk | 1 | 2008 | 903 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2008 | 1268 | 0.010 |
Why?
| | Pregnancy | 2 | 2008 | 7035 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2008 | 755 | 0.010 |
Why?
| | Health Status Indicators | 1 | 2004 | 161 | 0.010 |
Why?
| | Office Visits | 1 | 2003 | 94 | 0.010 |
Why?
| | Health Care Surveys | 1 | 2003 | 561 | 0.010 |
Why?
| | Disease Progression | 1 | 2008 | 2808 | 0.010 |
Why?
| | Biomarkers | 1 | 2008 | 4180 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2007 | 6270 | 0.010 |
Why?
|
|
Kruse's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|